drugset / Trial / NCT07671001
A Study of Depemokimab in Participants of 6 to 11 Years of Age
NaSingle-groupOpen-labelTreatment
Summary
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.
Timeline
- Start
- 2026-06-26
- Primary completion
- 2029-03-19
- Completion
- 2029-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Depemokimab | Protein / enzyme biologic | — | Subcutaneous |